Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03013491 · ClinicalTrials.gov registry record · Phase 1
PROCLAIM-CX-072: A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas
A Phase 1 study, sponsored by CytomX Therapeutics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 196
- Enrollment target
NCT03013491: Clinical Trial Phase 1 study, sponsored by CytomX Therapeutics.
NCT03013491 is a Phase 1 study that was terminated before completion, run by CytomX Therapeutics. The registered enrollment target is 196 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (227% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03013491, a Phase 1 study, was terminated before completion, sponsored by CytomX Therapeutics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 196 participants
- Enrollment target
Study Summary
The purpose of this first-in-human study of CX-072 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-072 administered intravenously (IV) as a single agent or in combination with ipilimumab or vemurafenib in adult subjects with advanced or recurrent solid tumors or lymphomas. PROCLAIM-CX-072: PRObody CLinical Assessment In Man CX-072 clinical trial CX-072 is a Probody® therapeutic directed against PD-L1 (programmed cell death ligand 1). Probody therapeutics are proteolytically-activatable antibodies (Abs) designed to widen the therapeutic index by minimizing drug interaction with normal tissue while retaining anti-tumor activity. Probody therapeutics are "masked" to attenuate binding to target in healthy tissue but can become "unmasked" in the tumor microenvironment by tumor-specific protease activity. PROBODY is a U.S. registered trademark of CytomX Therapeutics, Inc.
Primary Outcome
Adverse events (AEs) that were considered DLTs: * Grade 5 AEs * Grade 4 AEs judged by the Investigator to be treatment-related or judged by the Sponsor as a DLT, regardless of Investigator-attribution (with some exceptions) • Any Grade 4 endocrinopathy. * Grade 3 AEs judged by the Investigator to be treatment-related or by the Sponsor, regardless of Investigator-attribution (with some exceptions) • Any Grade 3 central nervous system event, regardless of duration or reversibility. * Grade
Interventions
- DRUG ipilimumab
- DRUG vemurafenib
- DRUG CX-072
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 196 participants |
| Start Date | 2017-01-19 |
| Est. Completion | 2020-10-27 |
| Phase | Phase 1 |
Why NCT03013491 stopped before completion
NCT03013491 is an interventional study that assigns participants to a tested intervention. The registered 196 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (227% higher).
The record links to 0 conditions, and to 3 interventions - of which ipilimumab is the first listed.
NCT03013491 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03013491 about?
NCT03013491 is a clinical study titled "PROCLAIM-CX-072: A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas". The purpose of this first-in-human study of CX-072 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-072 administered intravenously (IV) as a single agent or in combination with ipilimumab or vemurafenib in adult subjects with adva...
What is the current status of trial NCT03013491?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 196 participants. The study started on 2017-01-19. Estimated completion is 2020-10-27.
What interventions are being tested in trial NCT03013491?
The interventions under investigation include: ipilimumab (DRUG), vemurafenib (DRUG), CX-072 (DRUG).
Who is sponsoring clinical trial NCT03013491?
This trial is sponsored by CytomX Therapeutics, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03013491's enrollment target sits among peer trials
196 279th of 2000 higher than 1,720 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02822768 · 196 participants · NA
Packing Versus no Packing for Cutaneous Abscess
- NCT04250259 · 196 participants · Phase 2
SAMe Trial for Patients With Alcoholic Cirrhosis
- NCT05142592 · 196 participants · Phase 1
Phase1/2a Study for IPG7236 in Patients With Advanced Solid Tumors
- NCT05317832 · 196 participants · Phase 2
Using Smartphones to Improve Physical Activity Levels of Individuals With Spinal Cord Injury
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI